论文部分内容阅读
目的:研究讨论阿托伐他汀联合尿激酶治疗ST段抬高心肌梗死治疗效果。方法:回顾该医院收治急性ST段抬高型心梗患者70例,依照不同治疗方法分为A、B两组,A组为常规尿激酶溶栓治疗组,B组为阿托伐他汀联合尿激酶溶栓组,观察记录两组患者白细胞介素-6(IL-6)、超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)改变状况,记录所有患者ST段回落时间、胸痛缓解及酶峰出现时间。结果:治疗后A、B两组患者相比,A组患者IL-6、hs-CRP及TNF-α状况皆优于B组,差异有统计意义(P<0.05),患者ST段回落时间、胸痛缓解及酶峰出现时间亦优于B组,差异有统计意义(P<0.05)。结论:阿托伐他汀联合尿激酶治疗ST段抬高心肌梗死,治疗效果优于单独使用尿激酶,前者具有更好溶栓效果,复发率亦低于后者,可于临床广泛运用。
Objective: To study the effect of atorvastatin combined with urokinase in the treatment of ST elevation myocardial infarction. Methods: A retrospective study of 70 patients with acute ST-segment elevation myocardial infarction in our hospital was divided into two groups according to different treatment methods: group A was treated with conventional urokinase thrombolysis; group B was treated with atorvastatin combined with urine Kinase group and thrombolysis group. The change of IL-6, hs-CRP and TNF-α in both groups were observed and recorded. All patients’ ST segment Fall time, chest pain relief and enzyme peak appeared time. Results: Compared with group B, the levels of IL-6, hs-CRP and TNF-α in group A were significantly higher than those in group B after treatment (P <0.05). The fall time of ST segment, Chest pain relief and peak time of the enzyme peak was also better than the B group, the difference was statistically significant (P <0.05). Conclusion: Combination of atorvastatin and urokinase in treatment of ST elevation myocardial infarction is superior to urokinase alone. The former has a better thrombolytic effect and the recurrence rate is lower than the latter. It can be widely used clinically.